Optimizing Radiopharmaceutical Drug Design: Evaluating Approved Therapies & Exploring Novel Chelator & Linker Approaches
Time: 11:30 am
day: Conference Day Two
Details:
- Exploring the advantages and disadvantages of target vehicles (such as small molecules, peptides, and antibodies)
- Outlining lessons learned from the current approved radiopharmaceuticals.
- Selection of radionuclides and chelating agents for the development of radiopharmaceuticals for theranostics (imaging and therapy)
